TrialDiabetes care2018

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.

Paresh Dandona et al.PubMed ↗Publisher ↗

No numbers read from the abstract.